Clinical trials: Metastatic Prostate Cancer
Prostate Cancer, Prostatic Neoplasm
68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
This study investigates if a new prostate-specific membrane antigen (PSMA) drug makes prostate cancer easier to identify in positron-emission tomography (PET) imaging.
- Conditions
- Prostate Cancer, Prostatic Neoplasm, Prostatic Neoplasms, Castration-Resistant, Prostatic Cancer Recurrent
- Trial name
- NCT03389451
- Testing
- Ga-68 PSMA-HBED-CC PET
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Michael Graham PhD, MD
Prostate Neoplasms
Novel Therapy Target in Metastatic Prostate Cancer
The aim of this study is to use multiomics sequencing to explore the molecular characteristics of metastatic prostate cancer (mPCa), especially metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NTTPro (NCT05577689)
- Testing
- Tissue
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
The purpose of this study is to evaluate the efficacy of [177Lu]Lu-PSMA-617 over a change of androgen receptor-directed therapy (ARDT) treatment in prolonging radiographic progression free survival (rPFS) in Chinese metastatic…
- Trial name
- NCT05658003
- Testing
- [177Lu]Lu-PSMA-617, ARDT, [68Ga]Ga-PSMA-11
- Where
- 15 sites in China
- Volunteers
- 63 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer
Ipilimumab, an antibody that blocks cytotoxic T-lymphocyte antigen 4, and GVAX have demonstrated anti-tumor activity in prostate cancer. Pre-clinical studies with this combination have demonstrated potent synergy.
- Trial name
- NCT01510288
- Testing
- GVAX and ipilimumab
- Where
- Netherlands
- Volunteers
- 28 people
- Sponsor
- Amsterdam UMC, location VUmc
Prostate Cancer
S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Monoclonal antibodies, such as anti-IL-6 chimeric monoclonal antibody, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00433446
- Testing
- CNTO 328
- Where
- 123 sites in United States
- Volunteers
- 62 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
Abiraterone Acetate Trial in African American Prostate Cancer Patients
This is a pilot study of abiraterone acetate in African American/Black patients with castration-resistant prostate cancer. The primary objective is to determine the correlation between germline polymorphisms and antitumor…
- Trial name
- NCT01735396
- Testing
- Abiraterone Acetate
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
This is a multicenter, open-label, phase II study of YL201 in China to evaluate the efficacy, safety, and PK characteristics of YL201 on mCRPC.
- Trial name
- NCT06241846
- Testing
- YL201 for Injection
- Where
- 24 sites in China
- Volunteers
- 100 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The main purpose of this study to determine the safety of an experimental medicine called 131I-MIP-1095. 131I-MIP-1095 is an investigational drug, meaning it has not been approved by the U.S. Food \& Drug Administration (FDA).
- Trial name
- NCT03030885
- Testing
- 131I-MIP-1095
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Metastatic Prostate Cancer
Casodex vs Placebo in Non-Metastatic Early Prostate Cancer
The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were…
- Trial name
- SPCG6 (NCT00672282)
- Testing
- Bicalutamide
- Where
- 54 sites in Denmark, Finland and 2 more
- Volunteers
- 1,218 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer, Colorectal Cancer
Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer
The Wnt proteins belong to a family of proteins that have been demonstrated to play a role in the formation and dissemination of tumours.
- Conditions
- Metastatic Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT02020291
- Testing
- Foxy-5
- Where
- Denmark
- Volunteers
- 31 people
- Sponsor
- WntResearch AB
Metastatic Castration-resistant Prostate Cancer
Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
This is an open-label, phase II umbrella trial assessing the anti-tumor activity of enfortumab alone and in combination with other anti-cancer agents in subjects with metastatic castration-resistant prostate cancer.
- Trial name
- ENCORE (NCT04754191)
- Testing
- Enfortumab vedotin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Utah
Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
Study K36-MCRPC-001 is the first in human clinical trial testing KTX-2001 alone and with darolutamide in men with metastatic castration-resistant prostate cancer.
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients, Metastatic Castration-resistant Prostate Cancer, mCRPC, mCRPC
- Trial name
- STRIKE-001 (NCT07103018)
- Testing
- KTX-2001, KTX-2001 + Darolutamide (NUBEQA®)
- Where
- 13 sites in United States
- Volunteers
- 144 people
- Sponsor
- K36 Therapeutics, Inc.
Prostate Cancer
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that increases the immune system's ability to destroy…
- Trial name
- NCT04946370
- Testing
- 225Ac-J591, Pembrolizumab, Androgen receptor inhibitor
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Weill Medical College of Cornell University
Cancer
A Pharmacokinetic Study of Genistein, a Tyrosine Kinase Inhibitor
Genistein is a natural product found in soy beans; its consumption has been associated with a low incidence of metastatic prostate cancer.
- Trial name
- NCT00001696
- Testing
- Genistein
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
The purpose of this study is to test if treatment with medications that reduce the male hormone level in the participant's body for a few months before surgery can shrink prostate cancer as much as possible, which might reduce…
- Trial name
- NCT03436654
- Testing
- Apalutamide, Abiraterone Acetate, Prednisone
- Where
- 11 sites in United States
- Volunteers
- 102 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill prostate tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have…
- Trial name
- NCT00010127
- Testing
- therapeutic autologous dendritic cells
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Duke University
Prostate Cancer
Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301 is an open-label, dose-escalation phase 1 study of PSMA ADC administered IV in subjects with progressive, castration-resistant, metastatic prostate cancer…
- Trial name
- NCT01414283
- Testing
- PSMA ADC
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Prostate Cancer
A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
The purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11 works by activating the immune system to find and kill cancer cells.
- Trial name
- NCT06347705
- Testing
- 2141-V11 Antibody
- Where
- 7 sites in United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Neoplasms
A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to determine the effect of abiraterone acetate plus prednisone on the conduction of electric charges within the heart and to determine the blood levels of abiraterone acetate following administration…
- Trial name
- NCT00910754
- Testing
- Abiraterone acetate, Prednisone
- Where
- 8 sites in United States, Canada
- Volunteers
- 33 people
- Sponsor
- Janssen Research & Development, LLC
Solid Tumor
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.
- Trial name
- LODESTAR (NCT04171700)
- Testing
- Rucaparib
- Where
- 19 sites in United States
- Volunteers
- 83 people
- Sponsor
- pharmaand GmbH